Takeda Pharmaceutical announced Wednesday that its board has approved the next phase of its ongoing multi-year restructuring under incoming CEO Julie Kim. The transformation will focus on upcoming product launches and the company's late-stage pipeline development.
The restructuring represents a continuation of Takeda's strategic overhaul that has been underway for several years. The Japanese pharmaceutical giant has been working to streamline operations and refocus its business priorities under new leadership.